America’s Mental Health Crisis: Can Science Help End the Medication Guessing Game?
Fast-Tracking Relief: How RxGenomix's ExactMeds is Pioneering DNA-Guided Mental Health TreatmentFRANKLIN, TN / ACCESSWIRE / August 7, 2023 / Mental...
Genetic Testing
United States Women Health Laboratory Testing Research Report 2023-2028: Focus on Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and Diagnostic Testing – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Women Health Laboratory Testing Market by Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and...
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is...
Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences
STONY BROOK, NY / ACCESSWIRE / July 18, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in...
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional...
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
SALT LAKE CITY, July 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the...
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
- Treatment with infigratinib at the Cohort 5 dose level resulted in a significant and robust increase in annual height...
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and responseSALT LAKE CITY, June 12, 2023...
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Respondents may view these behaviors...
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient careSALT LAKE...
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Love for Liam Foundation Announces Formation; Names Board; Will Host Second Annual Golf Outing & Benefit Dinner on May 5, 2023
PHILADELPHIA, March 20, 2023 (GLOBE NEWSWIRE) -- The Love for Liam Foundation, a 501(c)(3) nonprofit that seeks to raise awareness...
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up...
Porex Life Sciences Institute Expands Saletto® Filtered Saliva Collection Device to the Genetic Testing Market
Revolutionary saliva collection tool standardizes samples through the industry’s first and only filtered collection tip, producing ready-to-use samples that are...
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent...
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit...
Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU1...